Table 1. Demographic and clinical characteristics in participants with and without coronary atherosclerosis1.
| Characteristics | All participants (N = 115) | No coronary atherosclerosis (N = 44) | Coronary atherosclerosis (N = 71) | P-value |
|---|---|---|---|---|
| Age (years) | 53.7±9.5 | 49.9±9.7 | 56.1±8.7 | 0.001 |
| Male | 102 (88.7%) | 35 (79.6%) | 67 (94.4%) | 0.030 |
| Current smoker | 27 (23.7%) | 14(31.82) | 13(18.31) | 0.105 |
| Family history of premature myocardial infarction | 3 (2.6%) | 2(4.55) | 1(1.41) | 0.557 |
| Diabetes mellitus | 46 (40.0%) | 16 (36.4%) | 30(42.3%) | 0.530 |
| Hypertension | 52 (45.2%) | 15 (34.1%) | 37 (52.1%) | 0.059 |
| Dyslipidemia | 52 (45.2%) | 12 (27.3%) | 40 (56.3%) | 0.002 |
| Obesity | 63 (54.8%) | 24 (54.6%) | 39 (54.9%) | 0.968 |
| Hepatitis B | 9 (7.8%) | 5 (11.4%) | 4 (5.6%) | 0.450 |
| Hepatitis C | 3 (2.6%) | 2 (4.6%) | 1 (1.4%) | 0.557 |
| Chest pain | 20 (17.4%) | 6 (13.6%) | 14 (19.7%) | 0.403 |
| Dyspnoea | 21 (18.3%) | 8 (18.2%) | 13 (18.3%) | 0.986 |
| Duration of HIV diagnosis (years) | 12 (7–17) | 12 (8–5) | 13 (7–17) | 0.928 |
| History of AIDS | 24 (20.9%) | 11 (25.0%) | 13 (18.3%) | 0.391 |
| Duration of antiretroviral therapy (years) | 9 (5–13) | 9 (6–13) | 9 (5–13) | 0.714 |
| Current anti-retroviral drugs | ||||
| Tenofovir | 78 (67.8%) | 29 (65.9%) | 49 (69.0%) | 0.729 |
| Abacavir | 31 (27.0%) | 13 (29.5%) | 18 (25.4%) | 0.622 |
| NNRTI | 27 (23.5%) | 10 (22.7%) | 17 (23.9%) | 0.881 |
| Protease inhibitor | 19 (16.5%) | 6 (13.6%) | 13 (18.3%) | 0.512 |
| Integrase strand transfer inhibitor | 74 (64.3%) | 29 (65.9%) | 45 (63.4%) | 0.783 |
| Body weight (kg) | 74.0±13.9 | 75.4±15.1 | 73.1±13.2 | 0.381 |
| Body mass index (kg/m2) | 26.5±7.2 | 27.9±10.3 | 25.6±4.3 | 0.366 |
| Waist circumference (cm) | 91.6±11.6 | 91.9±12.8 | 91.4±10.8 | 0.805 |
| Systolic blood pressure (mmHg) | 133±18 | 130±16 | 136±19 | 0.247 |
| Diastolic blood pressure (mmHg) | 86±11 | 86±12 | 87±11 | 0.67 |
| CD4 count (cells/mm3) | 632 (451–840) | 666 (496–840) | 615 (419–865) | 0.295 |
| CD4:CD8 ratio | 0.83±0.36 | 0.95±0.36 | 0.76±0.35 | 0.003 |
| HIV RNA <50 copies/mL | 109 (94.8%) | 42(95.45) | 67(94.37) | 1.000 |
| Total cholesterol (mmol/L) | 4.70±1.08 | 4.77±1.03 | 4.65±1.12 | 0.559 |
| HDL (mmol/L) | 1.19±0.38 | 1.25±0.37 | 1.15±0.39 | 0.063 |
| LDL (mmol/L) | 2.55±0.89 | 2.71±0.87 | 2.44±0.89 | 0.120 |
| Triglycerides (mmol/L) | 1.9 (1.4–2.8) | 1.8 (1.2–2.4) | 2.2 (1.5–3.0) | 0.057 |
| Glucose (mmol/L) | 5.9 (5.2–6.8) | 5.6 (5.1–6.5) | 6.1 (5.3–7.1) | 0.124 |
| HbA1C (mmol/L) | 5.9 (5.6–6.7) | 5.9 (5.6–6.5) | 6.0 (5.6–6.7) | 0.274 |
| HOMA-IR | 2.3 (1.2–4.4) | 2.2 (1.1–3.1) | 2.3 (1.3–4.8) | 0.156 |
| Creatinine (μmol/L) | 88.2±16.5 | 85.6±16.2 | 89.7±16.6 | 0.195 |
| D-dimer (ng/mL) | 259 (177–353) | 224 (164–328) | 263 (177–351) | 0.405 |
| Fibrinogen (g/L) | 2.99±0.58 | 3.02±0.56 | 2.96±0.59 | 0.591 |
| C reactive protein (mg/L) | 1.4 (0.6–3.0) | 1.7 (0.6–3.6) | 1.4 (0.6–2.3) | 0.224 |
| sCD163 (ng/mL) | 626±144 | 622±150 | 629±141 | 0.943 |
| sCD14 (pg/mL) | 2228 (2131–2371) | 2232 (2077–2402) | 2226 (2139–2344) | 0.820 |
| Adiponectin (ng/mL) | 1305 (674–3277) | 1591 (744–3529) | 1233 (587–3115) | 0.299 |
1Data are presented as number (percentage), mean ± standard deviation, or median (interquartile range), as appropriate